AIM ImmunoTech Announces Completion Of Enrollment In Phase 2 Study Evaluating Ampligen For The Treatment Of Post-COVID Conditions
Portfolio Pulse from Happy Mohamed
AIM ImmunoTech Inc. has completed enrollment for its Phase 2 study of Ampligen, a potential treatment for post-COVID conditions. The study has enrolled 80 subjects who will receive either Ampligen or a placebo for 12 weeks. The company expects to complete dosing by Q4 2023 and release topline data by Q1 2024. The rapid enrollment pace underscores the urgent need for a therapeutic option to treat Long COVID with chronic fatigue-like symptoms.
August 08, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AIM ImmunoTech's completion of enrollment for its Phase 2 study of Ampligen may positively impact the company's stock in the short term. The rapid enrollment pace indicates a high demand for a therapeutic option for post-COVID conditions.
The completion of enrollment for AIM ImmunoTech's Phase 2 study of Ampligen indicates progress in the company's research and development efforts. This could boost investor confidence in the company's potential to bring a new therapeutic option to market, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100